These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1200 related items for PubMed ID: 24621088

  • 1. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H, Zong H, Cui Y, Li N, Zhang Y.
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [Abstract] [Full Text] [Related]

  • 2. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [Abstract] [Full Text] [Related]

  • 3. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J, Li X, Yang B, Wu C, Fan Y, Li H.
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [Abstract] [Full Text] [Related]

  • 4. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
    Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH.
    Asian J Androl; 2015 Aug; 17(6):1022-32. PubMed ID: 25994648
    [Abstract] [Full Text] [Related]

  • 7. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [Abstract] [Full Text] [Related]

  • 8. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV, Mete UK, Mandal AK, Singh SK.
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [Abstract] [Full Text] [Related]

  • 9. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, Viktrup L.
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
    Sun K, Sun F, Yao H, Zhang D, Wu G, Wang T, Wang J, Wu J.
    Am J Mens Health; 2020 Jan; 14(6):1557988320980180. PubMed ID: 33342335
    [Abstract] [Full Text] [Related]

  • 11. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
    Wang Y, Bao Y, Liu J, Duan L, Cui Y.
    Low Urin Tract Symptoms; 2018 Jan; 10(1):84-92. PubMed ID: 29341503
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C.
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A, Casabe A, Rodriguez Baigorri G, Cobreros C.
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, Rwabasonga B, Risk MC, Wilt TJ.
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [Abstract] [Full Text] [Related]

  • 19. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK.
    Cochrane Database Syst Rev; 2018 Nov 16; 11(11):CD010060. PubMed ID: 30480763
    [Abstract] [Full Text] [Related]

  • 20. [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].
    Jin Z, Xin ZC.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug 18; 43(4):632-5. PubMed ID: 21844982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.